DYAI
Dyadic International, Inc.0.9092
+0.0828+10%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
32.90MP/E (TTM)
-Basic EPS (TTM)
-0.22Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Regains Nasdaq compliance; milestones hit
Dyadic International regained Nasdaq compliance on October 1 and 3, 2025, closing prior deficiencies in market value and bid price after strong performance from September. The company hit key milestones, securing a $500,000 payment from Proliant for recombinant human albumin productivity and $250,000 from Inzymes for dairy enzyme advances, boosting its shift to revenue generation. Sampling ramps up across life sciences and nutrition products. Compliance restored.
8-K
Security Agreement Amendment
Dyadic International amended its Security Agreement on September 15, 2025, updating the list of secured parties for its Senior Secured Convertible Promissory Notes due March 8, 2027. The change adds a trust for CEO Mark Emalfarb's benefit, following his $1,000,000 note purchase and assignment. This bolsters insider alignment with noteholders. No other terms altered.
10-Q
Q2 FY2025 results
Dyadic International posted Q2 revenue of $966.6K, up 150% y/y from $385.9K, fueled by $503.2K in grant revenue from Gates Foundation and CEPI deals plus a $250K milestone from the Inzymes dairy enzyme license, while research and development revenue dipped 45% y/y to $213.4K amid fewer active collaborations. Operating loss narrowed to $1.7M from $2.0M y/y, thanks to higher topline and 11% lower G&A expenses, though R&D costs rose 22% y/y on internal initiatives. Net loss improved to $1.8M or $0.06 per share from $2.0M or $0.07, with EPS aligning to 30.1M diluted shares; the $0.1M gap between operating and net loss stems from interest expense. Cash stood at $2.1M with $3.3M in investments, offset by $5.0M in convertible notes at 8% due 2027, but an August equity offering added $5.3M for runway. Grants and milestones are building momentum. Nasdaq listing compliance remains a key watch point.
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
BVAXD
BioVaxys Technology Corp.
0.15-0.03
CDXS
Codexis, Inc.
1.68+0.05
CYDY
CytoDyn Inc.
0.32+0.02
DNTH
Dianthus Therapeutics, Inc.
41.40-0.52
DVAX
Dynavax Technologies Corporatio
10.78-0.07
DYN
Dyne Therapeutics, Inc.
19.55-0.04
MRVI
Maravai LifeSciences Holdings,
3.59-0.08
VICP
Vicapsys Life Sciences, Inc.
1.50+0.00
ZIVO
Zivo Bioscience, Inc.
9.00+0.00